Navigation Links
Protein compels ovarian cancer cells to cannibalize themselves

HOUSTON A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research.

The research team also found that expression of the protein, known as PEA-15, is an independent indicator of a woman's prospects for surviving ovarian cancer, said senior author Naoto T. Ueno, M.D., Ph.D. associate professor of breast medical oncology.

An analysis of ovarian cancer tumors from 395 women showed those with high expression of the PEA-15 had a median survival time of 50.2 months compared with 33.5 months for women with low levels of the protein in their tumors.

"These findings provide a foundation for developing a PEA-15 targeted approach for ovarian cancer and for clarifying whether this protein is a novel biomarker that can predict patient outcomes," Ueno said.

Ovarian cancer kills about 15,000 women in the United States annually, and is notoriously hard to diagnose in its early stages, when it is also most optimal to treat.

A series of lab experiments by first author Chandra Bartholomeusz, M.D., Ph.D., showed that high expression of PEA-15 inhibits the growth of ovarian cancer cells by killing cells via autophagy, or self-cannibalization, rather than by apoptosis. Removing PEA-15 from ovarian cancer cells led to a 115 percent increase in the number of cells compared with a control group of cells that still had the protein.

In apoptosis, defective cells die from self-induced damage to their nuclei and DNA complex. Autophagy kills when a cell entraps parts of its cytoplasm in membranes and digests the contents, leaving a cavity. When this goes on long enough, the cell essentially eats itself until it dies, its cytoplasm riddled with cavities.

Location, location, location

Ueno's research team has found that the protein works to inhibit cancer in two distinct ways depending on its location in the cell.

First, PEA-15 inhibits one of the prominent actors in the growth, differentiation and mobility of cells, a protein called extracellular signaling related kinase, or ERK. Activated ERK in the cell nucleus fuels cancer growth. The research team earlier found that PEA-15 binds to ERK in the nucleus and moves it out into the cytoplasm, preventing its growth effects.

Now they've found that PEA-15 in the cytoplasm induces autophagy in cancer cells, a second method of inhibiting cancer growth. "These two very different actions by PEA-15 are based on the location of the protein," Ueno said.

ERK is an inviting target for cancer therapy, Ueno noted, but so far no one has been able to develop a successful ERK inhibitor.

"PEA-15 offers us a new dimension for potentially targeting ERK," Ueno said. "We've shown with high levels of PEA-15, women with ovarian cancer are surviving longer." Levels of the protein in tumors also might affect how other drugs work against the disease. Similar research is under way in breast cancer with. PEA-15, which is short for phospho-enriched protein in astrocytes.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Lipoprotein Levels May Predict Womens Hypertension Risk
2. New laser method reproduces art masterworks to protein patterns
3. Protein can nurture or devastate brain cells, depending on its friends, researchers find
4. Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein
5. Omega Protein Reports 17 Cents Per Share Third Quarter Profit
6. Signaling between protein, growth factor is critical for coordinated cell migration
7. Quintet of proteins forms new, early-warning blood test before heart attack strikes
8. Cell Biosciences Introduces First Protein Analysis Kits
9. The Wellness(R) Core(R) Family Continues to Grow With New Higher Protein, Grain-Free Canned Varieties for Cats and Dogs
10. Key Blood Test Protein May Not Cause Heart Disease
11. Elaborate Network Drives When and Where Proteins Are Made
Post Your Comments:
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
(Date:6/23/2016)... , June 23, 2016  Guerbet announced today that ... Supplier Horizon Award . One of ... was recognized for its support of Premier members through ... clinical excellence, and commitment to lower costs. ... this recognition of our outstanding customer service from Premier," ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
Breaking Medicine Technology: